Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline for MDR Acinetobacter Baumannii Infections
NCT01342731Phase 4Unknown
- Sponsor
- Mahidol University
- Start
- Jul 2011
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tigecycline in Acinetobacter baumannii infection, sponsored by Mahidol University. Primary endpoint: Clinical outcomes on effectiveness at 28 days. Status: unknown.
02
Drugs
tigecycline
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT01342731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342731.